1 option
Colorectal Cancer Treatment Resistance : Mechanisms, Insights, Advances, and Solutions / Zodwa Dlamini, editor.
- Format:
- Book
- Language:
- English
- Subjects (All):
- Colon (Anatomy)--Cancer--Treatment.
- Colon (Anatomy).
- Rectum--Cancer.
- Rectum.
- Physical Description:
- 1 online resource (476 pages)
- Edition:
- First edition.
- Place of Publication:
- Cambridge, MA : Academic Press, [2025]
- Summary:
- Colorectal Cancer Treatment Resistance: Mechanisms, Insights, Advances and Solutions provide insights, knowledge, and potential solutions for healthcare professionals, researchers, and individuals affected by colorectal cancer.
- Contents:
- Front Cover
- Colorectal Cancer Treatment Resistance
- Copyright Page
- Contents
- List of contributors
- Preface
- Part 1: Understanding Colorectal Cancer Drug Resistance
- Part 2: Innovative Approaches to Overcoming Drug Resistance
- Part 3: Molecular Factors and Therapeutic Strategies
- Part 4: Future Perspectives and Advanced Research
- 1 Understanding colorectal cancer drug resistance
- 1 Unraveling the mystery of treatment resistance in colorectal cancer
- Abbreviations
- Introduction
- Drug resistance in colorectal cancer
- Future technologies in overcoming treatment resistance
- Overcoming treatment resistance
- Chemotherapy resistance
- Immunotherapy and immunomodulation in treatment resistance
- Targeting alternative splicing
- Nanomedicine
- ncRNA in reversing resistance in colorectal cancer
- Targeting genetic signatures in overcoming colorectal cancer resistance
- Surgical interventions
- Research advances in colorectal treatment resistance
- Microbes in colon cancer drug resistance
- Conclusion
- Conflicts of interest
- References
- 2 Mechanisms of treatment resistance in colorectal cancer
- Multifaceted mechanisms underlying treatment resistance
- Role of pharmacokinetics in the evolution of treatment resistance
- Increased drug excretion
- Drug target alteration
- DNA damage repair
- The role of tumor microenvironment stromal cells in the evolution of treatment-resistant colorectal cancer
- Mesenchymal stem cells
- Cancer-associated fibroblasts
- Immunosuppressive cells
- The role of adipocytes
- Why do certain therapies fail?
- Potential targets for intervention to overcome resistance
- Limitations
- Conflict of interest
- 3 Biomarkers and predictive factors in colorectal cancer treatment resistance
- Abbreviations.
- Introduction
- Biomarkers in colorectal cancer diagnosis, prognosis, therapy, and response
- Diagnostic biomarkers in colorectal cancer
- Prognostic biomarkers in colorectal cancer
- Predictive biomarkers in colorectal cancer
- Predictive factors in colorectal cancer treatment resistance
- Hypermethylation
- Tumor microenvironment
- Other factors
- Colorectal cancer exposome and disparities
- Effects of ecosystems on colorectal cancer
- Lifestyles factors and colorectal cancer
- Social variables and colorectal cancer
- Advances and integrated approaches in colorectal cancer prognostic biomarker discovery
- Genomics
- Proteomics
- Metabolomics
- Multiomics approaches
- Challenges and limitations
- Conclusions
- 4 Targeted therapies and precision medicine in colorectal cancer drug resistance
- List of abbreviations
- Innovative approaches that tailor treatments to the unique genetic and molecular characteristics
- Ground-breaking advances in precision medicine and FDA-accepted targeted therapies
- Bevacizumab
- Cetuximab
- Panitumumab
- Ziv-Aflibercept
- Regorafenib
- Ramucirumab
- Pembrolizumab
- Nivolumab
- Ipilimumab
- Encorafenib
- Molecular pathways of colorectal cancer and potential targeted therapies
- Rat sarcoma-mutation targeted therapy
- Serine/threonine-protein kinase B-Raf mutation targeted therapy
- Microsatellite Instability targeted therapy
- Neurotrophic tyrosine receptor kinase gene fusion targeted therapy
- The role of phytochemical-based targeted therapy in colorectal cancer
- Combination therapy measures
- 2 Innovative approaches to overcoming drug resistance
- 5 Overcoming chemotherapy resistance in colorectal cancer
- Introduction into colorectal cancer
- Strategies to overcome chemotherapy resistance in colorectal cancer
- Medications and supplements
- Metformin
- Ivermectin
- Dichloroacetate
- Bazedoxifene
- Enalapril
- Melatonin
- Vitamins
- S-adenosylmethionine
- Nonsteroidal antiinflammatory drugs
- Gene therapy
- Ribozymes
- RNA interference
- Antisense oligonucleotides
- Clustered regularly interspaced short palindromic repeats
- Epigenetic therapy
- Noncoding RNAs
- Protein inhibitors
- Inhibitors of common resistance-related proteins
- Epidermal growth factor receptor inhibitors
- Sphingosine 1 phosphate receptor modulators
- Natural herbal compounds
- Innovative drug delivery system
- Liposomes
- Hydrogels
- Nanocarriers
- Exosomes
- Combinational therapy
- Supportive care measures
- Conflict of Interest
- 6 Emerging treatment approaches for colorectal cancer treatment resistance
- Targeted therapies
- Antiangiogenic agents
- Human epidermal growth factor receptor 2-targeted therapies
- BRAF inhibitors
- Mismatch repair and microsatellite instability targeting
- PI3K/AKT/mTOR pathway inhibitors
- Wnt pathway inhibitors
- Human epidermal growth factor receptor 3-targeted therapies
- Immunotherapies
- Immune checkpoint inhibitors and the MSI-H/dMMR subset
- Expanding immunotherapy to microsatellite stable colorectal cancer
- Personalized vaccines and neoantigen targeting
- Chimeric antigen receptor T-cell therapy
- Bispecific antibodies and T-cell engagers
- Microbiome modulation and response to immunotherapy
- Combination therapies
- Personalized medicine strategies
- Limitations and outlook
- References.
- 7 Immunotherapy and immunomodulation in colorectal cancer treatment resistance
- Current immunotherapeutic strategies in metastatic colorectal cancer management
- Understanding immunotherapy resistance mechanisms in colorectal cancer
- Immunotherapy strategies for overcoming treatment resistance
- Overcoming resistance mechanisms
- Ten-eleven translocation 1
- Ring-finger protein 43
- Nuclear receptor coactivator 3
- Large tumor suppressor
- Neurogenic locus notch homolog protein 3
- Cyclic-AMP response element binding protein
- Remodeling the tumor microenvironment
- Combinational therapies and efforts to tailor therapy for individualized treatment
- Future directions and perspectives
- Opportunities in implementing innovative approaches and optimizing therapeutic outcomes
- Reshaping the landscape of colorectal cancer management
- 8 Splicing-associated drug resistance in colorectal cancer: targeting splicing signatures
- Alternate splicing events in colon cancer
- Cis regulatory elements
- Transregulatory factors in colorectal cancer
- Posttranslational alterations of transregulatory splicing factors
- Alternative splicing in drug resistance in colorectal cancer
- DNA damage response
- Resistance to apoptosis
- Invasion and metastasis
- Altering angiogenesis
- Targeting alternative splicing to reverse drug resistance
- Therapeutic approaches of small molecule inhibitors
- 9 Nanomedicine innovations: conquering colorectal cancer drug resistance
- Mechanisms of drug resistance in colorectal cancer
- Mechanism of action of nanoparticles.
- Use of nanoparticles to overcome colorectal cancer resistance to chemotherapy
- Nanoparticles loaded with cisplatin drugs
- Nanoparticles loaded with carboplatin drugs
- Nanoparticles and use of Oxaliplatin drug
- Solid lipid nanoparticles loaded with oxaliplatin
- Liposome loaded with oxaliplatin
- Polymeric nanoparticles loaded with oxaliplatin
- Challenges/limitations of using nanoparticles in cancer treatment
- Strategies to overcome the challenges of using nanoparticles
- Further reading
- 3 Molecular factors and therapeutic strategies
- 10 MicroRNAs in colorectal cancer drug resistance
- MicroRNA biogenesis and expression
- Altered microRNA expression and mechanisms of drug resistance of colorectal cancer
- MicroRNAs modulate autophagy in colorectal cancer drug resistance
- MicroRNAs regulate the cell cycle in colorectal cancer drug resistance
- MicroRNAs affect the ATP-binding cassette efflux pump in colorectal cancer drug resistance
- MicroRNAs affect deoxyribonucleic acid repair in drug resistance
- MicroRNAs and apoptosis in colorectal cancer drug resistance
- MicroRNAs and metabolism in colorectal cancer drug resistance
- Epithelial-mesenchymal transition
- MicroRNA-mediated signaling pathways in drug tolerance of CRC
- PI3K/AKT signaling pathway
- Wnt/β-catenin signaling pathway
- TGF-β signaling pathway
- Related signaling pathways and transcription factors
- MicroRNAs as therapeutic targets and agents to overcome drug resistance in colorectal cancer
- MicroRNA-based therapies to enhance treatment success in colorectal cancer
- Limitations and challenges of microRNAs therapeutics in colorectal cancer drug resistance
- 11 Long noncoding RNAs and drug resistance in colorectal cancer
- Introduction.
- Notes:
- Includes bibliographical references and index.
- Description based on publisher supplied metadata and other sources.
- Description based on print version record.
- ISBN:
- 9780443334764
- 0443334765
- 9780443334757
- 0443334757
- OCLC:
- 1470855969
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.